Skip to content
EntityQ106271348· pop 5· linked from 450 articles

Also known as DAB-452

Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.

Wikidata facts

Mass
310.131742436
Show 4 more facts
Commons category
Aplindore
canonical SMILES
C1C(OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4
isomeric SMILES
C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4
chemical formula
C₁₈H₁₈N₂O₃

via Wikidata · CC0

~1 min read

Encyclopedic overview

2 sections
Contents
  • See also
  • References

Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.

On December 23, 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger. As of 2008, Phase II was completed and Ligand.

Excerpted from Wikipedia’s “aplindore” article, available under the CC BY-SA 4.0 licence.

Available in 4 languages

via Wikidata sitelinks · CC0